Summaries of health policy coverage from major news organizations
‘Breakthrough’ Merck AIDS Drug to Move Into Human Trials Next Year
Merck & Co. announced Tuesday at a meeting of analysts and investors that its new AIDS drug will move into human trials next year, Reuters/Contra Costa Times reports. The drug, which works by blocking the integrase enzyme, could be a "potential 'breakthrough' medicine," according to the company. Merck also said that progress continues on its HIV/AIDS vaccine candidate and the company remains "hopeful of its eventual effectiveness" (Reuters/Contra Costa Times, 12/11).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.